• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kempharm Inc (NQ: KMPH )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Feb 28, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 5.690 (8)
    Ask (Size) 6.000 (20)
    Prev. Close 5.810
    Today's Range N/A - N/A
    52wk Range N/A - N/A
    Shares Outstanding 33,932,639
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
    From KemPharm
    Via GlobeNewswire
    KemPharm Announces Corporate Name Change to Zevra Therapeutics
    From KemPharm
    Via GlobeNewswire

    Performance

    More News

    Read More
    This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
    Via Benzinga
    KemPharm's Earnings: A Preview
    Via Benzinga
    KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
    Via Benzinga
    Recap: KemPharm Q2 Earnings
    Via Benzinga
    KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
    Via Benzinga
    KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
    Via Benzinga
    US Stocks Turn Lower; Nasdaq Drops Over 100 Points
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
    Via Benzinga
    Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
    Via Benzinga
    Recap: KemPharm Q1 Earnings
    Via Benzinga
    Earnings Preview For KemPharm
    Via Benzinga
    The Technology Helping Existing FDA-Approved Drugs Target More Effectively
    Via Benzinga
    Benzinga Announces This Week's All Access Guests
    Via Benzinga
    26 Stocks Moving in Monday's Pre-Market Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
    Via Benzinga
    Earnings Scheduled For March 30, 2022
    Via Benzinga
    KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
    Via Benzinga
    The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
    Via Benzinga
    38 Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
    Via Benzinga
    65 Biggest Movers From Yesterday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.